Skip to main content
. 2021 Apr 26;15(7):1921–1941. doi: 10.1002/1878-0261.12954

Fig. 1.

Fig. 1

LINC00261 is associated with NEPC. (A) Expression of (TaqMan qPCR) of select lincRNAs that are upregulated in NEPC in the LTL‐331/331R PDX model. (B) Relative expression (microarray) of LINC00261 in several PDX models of prostate adenocarcinoma (n = 13) and NEPC (n = 4) from the Living Tumor Laboratory. (C) Relative expression (qPCR) of LINC00261 in FFPE biopsy samples from NEPC (n = 11) and CRPC‐Adeno (n = 8) patients. (D) Expression of LINC00261 (RNA‐seq) in patient specimens with features of neuroendocrine (n = 15) or castration‐resistant (n = 34) disease. Datasets used is from Ref. (Barbieri et al. [54]; Beltran et al. [16]) (E) LINC00261 expression in patient samples with or without AR copy gains (**P = 0.0025), or (F) AKT2 copy gains, an activating component of the PI3K/AKT pathway (*P = 0.0197). (G) LINC00261 expression in clinical PCa biopsies from secondary lesions in the prostate/lymph nodes (n = 25), bone (n = 29), or liver (n = 17; ***P < 0.001, ANOVA and Tukey's post hoc test). Data from cBioPortal, Metastatic PCa SU2C/PCF Dream Team Cell, 2015. Data in B–E were analyzed by two‐tailed unpaired t‐test. All data are presented as mean ± SEM with at least two independent biological replicates.